Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer

J. C. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong, K. H. Lee, A. Dechaphunkul, F. Imamura, N. Nogami, T. Kurata, I. Okamoto, C. Zhou, ByoungChul Cho, Y. Cheng, E. K. Cho, P. J. Voon, D. Planchard, W. C. Su, J. E. Gray, S. M. Lee & 4 others R. Hodge, M. Marotti, Y. Rukazenkov, S. S. Ramalingam

Research output: Contribution to journalArticle

505 Citations (Scopus)

Abstract

BACKGROUND Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-Assessed progression-free survival. RESULTS The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). CONCLUSIONS Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials .gov number, NCT02296125.).

Original languageEnglish
Pages (from-to)113-125
Number of pages13
JournalNew England Journal of Medicine
Volume378
Issue number2
DOIs
Publication statusPublished - 2018 Jan 11

Fingerprint

Non-Small Cell Lung Carcinoma
Confidence Intervals
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
Disease-Free Survival
osimertinib
Disease Progression
Exons
Survival Rate
Odds Ratio
Research Personnel
Safety
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., ... Ramalingam, S. S. (2018). Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125. https://doi.org/10.1056/NEJMoa1713137
Soria, J. C. ; Ohe, Y. ; Vansteenkiste, J. ; Reungwetwattana, T. ; Chewaskulyong, B. ; Lee, K. H. ; Dechaphunkul, A. ; Imamura, F. ; Nogami, N. ; Kurata, T. ; Okamoto, I. ; Zhou, C. ; Cho, ByoungChul ; Cheng, Y. ; Cho, E. K. ; Voon, P. J. ; Planchard, D. ; Su, W. C. ; Gray, J. E. ; Lee, S. M. ; Hodge, R. ; Marotti, M. ; Rukazenkov, Y. ; Ramalingam, S. S. / Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. In: New England Journal of Medicine. 2018 ; Vol. 378, No. 2. pp. 113-125.
@article{e880ec669dbf498eb544a36223c628fb,
title = "Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer",
abstract = "BACKGROUND Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-Assessed progression-free survival. RESULTS The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95{\%} confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80{\%} with osimertinib and 76{\%} with standard EGFR-TKIs (odds ratio, 1.27; 95{\%} CI, 0.85 to 1.90; P = 0.24). The median duration of response was 17.2 months (95{\%} CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95{\%} CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25{\%} maturity). The survival rate at 18 months was 83{\%} (95{\%} CI, 78 to 87) with osimertinib and 71{\%} (95{\%} CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95{\%} CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34{\%} vs. 45{\%}). CONCLUSIONS Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials .gov number, NCT02296125.).",
author = "Soria, {J. C.} and Y. Ohe and J. Vansteenkiste and T. Reungwetwattana and B. Chewaskulyong and Lee, {K. H.} and A. Dechaphunkul and F. Imamura and N. Nogami and T. Kurata and I. Okamoto and C. Zhou and ByoungChul Cho and Y. Cheng and Cho, {E. K.} and Voon, {P. J.} and D. Planchard and Su, {W. C.} and Gray, {J. E.} and Lee, {S. M.} and R. Hodge and M. Marotti and Y. Rukazenkov and Ramalingam, {S. S.}",
year = "2018",
month = "1",
day = "11",
doi = "10.1056/NEJMoa1713137",
language = "English",
volume = "378",
pages = "113--125",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "2",

}

Soria, JC, Ohe, Y, Vansteenkiste, J, Reungwetwattana, T, Chewaskulyong, B, Lee, KH, Dechaphunkul, A, Imamura, F, Nogami, N, Kurata, T, Okamoto, I, Zhou, C, Cho, B, Cheng, Y, Cho, EK, Voon, PJ, Planchard, D, Su, WC, Gray, JE, Lee, SM, Hodge, R, Marotti, M, Rukazenkov, Y & Ramalingam, SS 2018, 'Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer', New England Journal of Medicine, vol. 378, no. 2, pp. 113-125. https://doi.org/10.1056/NEJMoa1713137

Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. / Soria, J. C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, ByoungChul; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W. C.; Gray, J. E.; Lee, S. M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.

In: New England Journal of Medicine, Vol. 378, No. 2, 11.01.2018, p. 113-125.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer

AU - Soria, J. C.

AU - Ohe, Y.

AU - Vansteenkiste, J.

AU - Reungwetwattana, T.

AU - Chewaskulyong, B.

AU - Lee, K. H.

AU - Dechaphunkul, A.

AU - Imamura, F.

AU - Nogami, N.

AU - Kurata, T.

AU - Okamoto, I.

AU - Zhou, C.

AU - Cho, ByoungChul

AU - Cheng, Y.

AU - Cho, E. K.

AU - Voon, P. J.

AU - Planchard, D.

AU - Su, W. C.

AU - Gray, J. E.

AU - Lee, S. M.

AU - Hodge, R.

AU - Marotti, M.

AU - Rukazenkov, Y.

AU - Ramalingam, S. S.

PY - 2018/1/11

Y1 - 2018/1/11

N2 - BACKGROUND Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-Assessed progression-free survival. RESULTS The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). CONCLUSIONS Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials .gov number, NCT02296125.).

AB - BACKGROUND Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-Assessed progression-free survival. RESULTS The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). CONCLUSIONS Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials .gov number, NCT02296125.).

UR - http://www.scopus.com/inward/record.url?scp=85040652883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040652883&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1713137

DO - 10.1056/NEJMoa1713137

M3 - Article

VL - 378

SP - 113

EP - 125

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. New England Journal of Medicine. 2018 Jan 11;378(2):113-125. https://doi.org/10.1056/NEJMoa1713137